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Background:While disease categories (i.e. clinical phenotypes) of multiple sclerosis (MS) are established, there re-
mains MRI heterogeneity among patients within those deﬁnitions. MRI-deﬁned lesions and atrophy show only
moderate inter-correlations, suggesting that they represent partly different processes inMS.Weassessed the ability
of MRI-based categorization of cerebral lesions and atrophy in individual patients to identify distinct phenotypes.
Methods: We studied 175 patients with MS [age (mean ± SD) 42.7 ± 9.1 years, 124 (71%) women, Expanded
Disability Status (EDSS) score 2.5 ± 2.3, n = 18 (10%) clinically isolated demyelinating syndrome (CIS), n = 115
(66%) relapsing-remitting (RR), andn=42 (24%) secondary progressive (SP)]. BrainMRImeasures includedT2hy-
perintense lesion volume (T2LV) and brain parenchymal fraction (to assess whole brain atrophy). Medians were
used to create bins for each parameter, with patients assigned a low or high severity score.
Results: Four MRI phenotype categories emerged: Type I = low T2LV/mild atrophy [n = 67 (38%); CIS = 14,
RR = 47, SP = 6]; Type II = high T2LV/mild atrophy [n = 21 (12%); RR = 19, SP = 2]; Type III = low T2LV/
high atrophy [n = 21 (12%); CIS = 4, RR = 16, SP = 1]; and Type IV = high T2LV/high atrophy [n = 66
(38%); RR=33, SP= 33]. Type IVwas themost disabled andwas the only group showing a correlation between
T2LV vs. BPF and MRI vs. EDSS score (all p b 0.05).
Conclusions:WedescribedMRI-categorization based on the relationship between lesions and atrophy in individ-
ual patients to identify four phenotypes in MS. Most patients have congruent extremes related to the degree of
lesions and atrophy. However, many have a dissociation. Longitudinal studies will help deﬁne the stability of
these patterns and their role in risk stratiﬁcation.
© 2014 Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
While clinically-deﬁned disease categories of multiple sclerosis
(MS) are well established [1], there remains heterogeneity of the
disease among patients that appears to exist within the conﬁnes of
these subtypes. This heterogeneity includes the concepts of patient-
dependent longitudinally-consistent immunopathological lesion
subtypes [2] and clustering of patient subgroups based on MRI-deﬁned
lesion characteristics and the level of tissue destruction [3,4]. Consistent
with the concept of disease heterogeneity, clinical progression and treat-
ment response are difﬁcult to predict in individual patients. Furthermore,
there is a topographic uncoupling of structural changes such as the lack
of a relationship between brain and spinal cord involvement [5]. Takeng Research, One Brookline Place,
.
ticle under the CC BY-NC-SA license (together, these data suggest that the pathogenesis of tissue injury may
differ among patients with MS.
Among the types of CNS tissue injury that typify the disease, the two
broadest categories include inﬂammatory demyelinating foci (lesions)
and tissue destruction (neurodegeneration; axonal and neuronal loss).
The most commonly-used and readily-available MRI measure of lesion
load is hyperintensity on T2-weighted images. To assess overall tissue
destruction, MRI-quantiﬁed normalized whole brain volume is an
established measure of brain atrophy [6]. Several lines of evidence
indicate that lesions and atrophy represent somewhat unrelated aspects
of the disease process. This includes the observation that in both cross-
sectional [6,7] and longitudinal [6,8] studies, lesions show a weak
relationship to current and subsequent atrophy. Furthermore, the two
measures provide complementary information in predicting treatment
efﬁcacy [9]. The objective of this study was to assess the ability of
MRI-based categorization of the relationship between the severity of ce-
rebral lesions and atrophy in individual patients to identify distinct MS
phenotypes. This work was presented in preliminary form at the 2013
annual meeting of the American Academy of Neurology, San Diego.http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1.Method of creation of MRI-based phenotypes. Patients were stratiﬁed by median
splits of the entire cohort based on total cerebral MRI-measures of inﬂammation (T2LV)
and atrophy (BPF); the median was used to create bins for each MRI parameter, with
patients assigned a score of low or high severity; T2LV = total brain T2 hyperintense
lesion volume (cc); BPF = brain parenchymal fraction; A = atrophy; L = T2LV; Type I
(mild atrophy/low T2LV); Type II (mild atrophy/high T2LV); Type III (high atrophy/low
T2LV); Type IV (high atrophy/high T2LV).
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2.1. Subjects and clinical evaluation
Demographic and clinical characteristics of the subjects are summa-
rized in Table 1. This was a single-center cross-sectional retrospective
study of 175 consecutive patients who met the following inclusion
criteria: 1) Diagnosed with a relapsing form of MS including a
clinically-isolated demyelinating syndrome (CIS), relapsing-remitting
(RR), or secondary progressive (SP) [1]; 2) Evaluated clinically by an
MS specialist provider at the Brigham and Women's Hospital MS clinic
(Partners MS Center) within three months of MRI; 3) age 18–60 years.
Nearly all patients were receiving disease modifying therapy, as is the
common practice at our center [7]. Baseline characteristics, including
demographic, clinical, and MRI (Table 1), were comparable to those of
large MS cohorts [10,11], indicating that our cohort represented a
wide range of the MS spectrum that includes the continuum CIS–RR–
SP. We did not include primary progressive MS patients because of the
challenging diagnosis [1], the small numbers of those patients available,
and that concept that this group may represent a separate entity. This
study was approved by our institutional review board.
2.2. MRI acquisition and segmentation
Brain MRI was obtained in all subjects at 1.5 T with a 3 mm thick,
gapless, T2-weighted, axial dual-echo protocol that included the entire
brain. With few exceptions, the protocol was performed on the same
scanner and included the following consistent acquisition parameters:
repetition time 3000 ms, echo time 30/80 ms, and 0.93 × 0.93 mm
pixel size. Using automated template-driven segmentation (TDS+)
from the dual echo images, total brain T2 hyperintense white matter
lesion volume (T2LV) and normalized whole brain volume [brain
parenchymal fraction (BPF) — a surrogate of whole brain atrophy] [6]
were automatically determined [12], after which expert manual correc-
tion was applied to each output map to ensure accuracy.
2.3. Creation of the MRI-deﬁned phenotypes
Patients were stratiﬁed into MRI phenotype groups based on a
median split (0 or 1) of T2LV and BPF. As shown in Fig. 1, all patients
were assigned to one of four unique groups as:
Type I = mild atrophy (0) and low T2LV (0)
Type II = mild atrophy (0) and high T2LV (1)
Type III = high atrophy (1) and low T2LV (0)
Type IV = high atrophy (1) and high T2LV (1).
2.4. Statistical analysis
The demographic, clinical and MRI characteristics were compared
across the four groups using one-way analysis of variance for continuous
outcomes (age, disease duration, BPF, and T2LV), a proportional odds
model for ordinal outcomes (EDSS) and a chi-square test for nominalTable 1
Demographic and clinical characteristics of the subjects.
Number of patients n = 175
Clinical MS phenotype:
• Clinically isolated syndrome n = 18 (10%)
• Relapsing-remitting MS n = 115 (66%)
• Secondary progressive MS n = 42 (24%)
Number of women (n, %) n = 124 (71%)
Age (mean ± SD) (range) (years) 42.7 ± 9.1 (21–60)
Expanded Disability Status Scale score 2.5 ± 2.3 (0–8.6)
Disease duration (years since ﬁrst symptoms) 9.6 ± 8.6 (0.2–48.0)
Total brain T2 hyperintense lesion volume (cc) 8.7 ± 10.2 (0.5–57.1)
Brain parenchymal fraction 0.844 ± 0.049 (0.67–0.96)variables (gender and disease category). If a signiﬁcant difference was
observed in the four group comparison, pairwise group comparisons
were completed and Holm's correction for multiple comparisons was
applied to adjust the p-values. In addition, we assessed the relationship
among the MRI measures and the relationship between MRI and EDSS
score using the Spearman's correlation coefﬁcient. These were analyzed
for the whole cohort and within each MRI phenotype group.
3. Results
Four categories emerged from the median split analysis (Table 2,
Fig. 2). Regarding clinical and demographic group comparisons
(Table 2), Type IV patients had higher disease duration, higher EDSS
scores, and a higher proportion of SP patients than the other three
groups (all p b 0.05). Type III and IV patients were each older than the
Type I and II patients. Otherwise, there were no differences in age, dis-
ease duration, EDSS score, or clinical disease category distribution
among groups (p b 0.05). There were no differences in the gender
breakdown across the groups (p N 0.05).
Regarding the MRI parameters that comprised the phenotypes
(Table 2), all pairwise comparisons showed signiﬁcant differences in
T2LV among the groups (p b 0.05), except for Type I vs. Type III
(p N 0.05). In addition, all pairwise comparisons showed signiﬁcant dif-
ferences in BPF among the groups (p b 0.05) except Type I vs. Type II
(p N 0.05). These results conﬁrm the rationale of deﬁning unique MRI
phenotypes on the basis of different T2LV and BPF characteristics.
We also tested the relationships between lesions and atrophy and
between MRI and disability (Table 3). The correlation between T2LV
and BPF was signiﬁcant in the overall cohort (p b 0.0001) and in the
Type IV patients (p b 0.0001) but not in the other three groups
(p N 0.05). Similarly, the correlation between each of the two MRI pa-
rameters (T2LV and BPF) and EDSS score was signiﬁcant in the overall
cohort (p b 0.0001) and in the Type IV patients (p b 0.0001) but not
in the other three groups (p N 0.05).
4. Discussion
A major ﬁnding in this study is that 25% patients had a discordance
of where their brain lesions and atrophy fell with regard to themedians
of the full cohort. The discordance was equally bidirectional in that
about half of the discordant patients had a high degree of atrophy
Table 2
Demographic, clinical and MRI characteristics of the MRI-deﬁned phenotypes.
Type I (mild atrophy/
low T2LV)
Type II (mild atrophy/
high T2LV)
Type III (high atrophy/
low T2LV)
Type IV (high atrophy/
high T2LV)
Number of patients (%) n = 67 (38%) n = 21 (12%) n = 21 (12%) n = 66 (38%)
Disease category:
• Clinically isolated syndrome 14 (21%) 0 4 (19.0%) 0
• Relapsing-remitting MS 47 (70%) 19 (91%) 16 (76%) 33 (50%)
• Secondary progressive MS 6 (9%) 2 (9%) 1 (5%) 33 (50%)
Number of women (n, %) n = 51 (76%) n = 16 (76%) n = 14 (67%) n = 43 (65%)
Age (mean ± SD) (range) (years) 37.3 ± 8.3 (21.0–54.1) 36.9 ± 7.9 (21.7–50.2) 43.7 ± 7.8 (21.0–54.3) 44.0 ± 8.6 (26.5–60.2)
Expanded Disability Status Scale score 1.5 ± 1.8 (0–8.5) 1.9 ± 2.0 (07.5) 1.7 ± 1.8 (0–6.5) 3.9 ± 2.2 (1.0–8.5)
Disease duration (years) 5.5 ± 5.7 (0.26–26.0) 8.6 ± 6.6 (0.57–22.0) 8.6 ± 8.1 (0.4–26.0) 14.3 ± 9.4 (0.25–48.0)
T2LV (cc) 2.3 ± 1.0 (0.46–4.21) 8.2 ± 4.9 (4.5–22.2) 2.3 ± 1.1 (0.8–4.1) 17.3 ± 11.8 (4.4–57.1)
Brain parenchymal fraction 0.888 ± 0.025 (0.85–0.93) 0.875 ± 0.025 (0.85–0.93) 0.834 ± 0.016 (0.78–0.85) 0.791 ± 0.041 (0.67–0.85)
Key: T2LV = total brain T2 hyperintense lesion volume. Regarding the breakdown of women vs. men, no signiﬁcant differences were observed across the groups (p N 0.05). Regarding
age, Types III and IV were signiﬁcantly older than Types I and II (p b 0.05). Regarding disease category (i.e. clinical phenotype), EDSS, and disease duration, Type IV was signiﬁcantly
more likely to be SPMS, disabled, with higher disease duration than the other three categories (p b 0.05). Regarding T2LV, all pairwise differences except Type I vs III were statistically
signiﬁcant (p b 0.05). Regarding brain parenchymal fraction, all pairwise differences except Type I vs. Type II were statistically signiﬁcant (p b 0.05).
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III). This was further underscored by the poor correlation in both groups
between T2LV and BPF. Taken together these ﬁndings suggest that sub-
groups of patients have an uncoupling between focal immune-
mediated demyelination in white matter (inﬂammation) and overall
global cerebral tissue destruction (neurodegeneration).
Regarding the Type II patients, who have a high T2LV but low atro-
phy, this might relate in part to the long held view that T2 hyperintense
lesions are non-speciﬁc for pathologic changes, reﬂecting a wide range
of severity [13]. We hypothesize that Type II patients have a T2LV that
is dominated by mild changes such as mild inﬂammation, edema, and
partial demyelination. Another factor serving to limit overall atrophy
in these patients may be the presence of enhanced repair capacity [14]
or other resistance to the downstream effects of white matter injury
on neuronal and axonal integrity.
Regarding the Type III patients, who have a low T2LV but higher de-
gree of atrophy, there may be other contributions to tissue destruction
that are not captured by overt lesion load. Considering the prevailing
notion that whole brain atrophy in MS is dominated by gray matter
rather than white matter atrophy, consistently seen in MRI studies at
1.5 T and 3 T [6,15–17], the Type III patients may be affected by grayFig. 2. Representative proton densityMRI scans showing theMRI-deﬁned phenotypes. Four pat
II (mild atrophy/high T2LV); Type III (high atrophy/lowT2LV); Type IV (high atrophy/high T2LV
duration (years); T2LV = total brain T2 hyperintense lesion volume (cc); BPF = brain parencmatter injury due to a variety of mechanisms that are separate from
white matter lesions (and were not assessed in the present study)
such as microglial activation [18], cortical lesions [19,20], meningeal
inﬂammation [21], and iron deposition/oxidative stress [22].
Type 1 and Type IV phenotypes were characterized by a congruent
level of lesions and atrophywith each either of a lower (Type I) or higher
(Type IV) degree. Comparing these two groups, Type I patients tended to
be at an earlier stage of disease on other disease characteristics, showing
a lower age, lower disease duration, and lower level of disability. In
addition, the Type I group was represented by a preponderance of CIS
or RR rather than SP patients. Type IV patients representmore advanced
disease, owing to the higher disease duration and higher disability level
than the other three groups.
Another noteworthy ﬁnding in this study is that theMRI phenotypes
belie the conﬁnes of the current MS disease categories (i.e. clinical
phenotypes), readily crossing those boundaries, suggesting that the
MRI categorization provides unique information about disease severity.
For example, RR and SP patients were identiﬁed in each of the four MRI
phenotype groups, in a manner that would contradict the intuitive
understanding of these clinical stages of MS. In particular, 9% of the
Type I (mild) MRI phenotype patients had a SP (advanced) clinicalients are shown as examples of the four phenotypes; Type I (mild atrophy/low T2LV); Type
); RR= relapsing-remitting; EDSS= ExpandedDisability Status Scale score; DD= disease
hymal fraction.
Table 3
MRI–MRI and MRI–disability correlations.
Correlation examined Type I (n = 67) Type II (n = 21) Type III (n = 21) Type IV (n = 66) Entire cohort (n = 175)
T2LV–BPF −0.06 (0.656) −0.16 (0.491) −0.32 (0.158) −0.49 (b0.0001)⁎ −0.66 (b0.0001)⁎
BPF–EDSS −0.35 (0.003)⁎ −0.21 (0.356) 0.30 (0.185) −0.46 (0.0001)⁎ −0.57 (b0.0001)⁎
T2LV–EDSS 0.11 (0.383) 0.18 (0.433) 0.28 (0.225) 0.36 (0.003)⁎ 0.56 (b0.0001)⁎
Key: rs (p) values are shown for Spearman correlation coefﬁcients; Type I (mild atrophy/low T2LV); Type II (mild atrophy/high T2LV); Type III (high atrophy/low T2LV); Type IV (high
atrophy/high T2LV); EDSS = Expanded Disability Status Scale score; T2LV = total brain T2 hyperintense lesion volume (cc); BPF = brain parenchymal fraction.
⁎ p b 0.05.
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progressed to SP). This paradox is underscored by the fact that the range
of EDSS scores was similar between Type I and Type IV groups. Spinal
cord involvement (not considered in the present study) might explain
the presence of SP patients in the Type I MRI group, given that spinal
cord atrophy is a hallmark of SPMS [23] and such involvement is poorly
reﬂected in MRI brain measures of pathology [5]. Why are there so
many patients with Type IV pathology in the RR (rather than SP) stage
and carrying relatively low levels of disability? These patients may
have enhanced cerebral reserve capacity [24], sparing of eloquent sub-
structures/pathways of the brain [25], or relative little spinal cord
involvement [5] (analyses which were not performed in the present
study). Because this was a cross-sectional study, we were not able to
determine if the more mildly affected Type IV patients were at risk for
imminent clinical progression. As further evidence of the unique
information provided by the MRI phenotype grouping, Type II and
Type III patients showed a similar number of RR and SP patients.
A longstanding challenge in the MS ﬁeld has been the poor correla-
tion between brain MRI and neurologic status [26]; this clinical–MRI
paradox has traditionally referred to focal brain lesions.Whilemeasure-
ment of brain atrophy has improved MRI correlations with disability
and cognitive impairment, the association with clinical status has
remained inconsistent (and moderate at best) [5–8, 15–17, 19, 26–28].
In the present study, we found a striking difference among groups in
modeling the relationship between brain MRI and disability in that
three of the groups (Types I, II and III) showed no relationship between
either T2LV or BPF and EDSS score; while, Type IV patients showed sig-
niﬁcant but moderate associations. Our data thus indicate that disease
heterogeneity is one factor contribution to the relationship between
global MRI and physical disability. Moreover we can bring forward a
“two-hit” hypothesis based on these results that both inﬂammation
and neurodegeneration need to be substantially present in a given pa-
tient to exceed cerebral reserve capacity and thus cause clinical
impairment.
Perhaps the ﬁrst use of a clustering method to classify patients with
MS on the basis of MRI-deﬁned inﬂammation or neurodegeneration
was introduced by Bielekova et al. [3]. These investigators used the
presence of gadolinium-enhancement on three consecutive monthly
scans to initially stratify patients as having either low or high active
inﬂammation. Subjects were then subdivided further by BPF and the
ratio of T1 hypointense to T2 hyperintense lesions. Although related,
ours was a more simpliﬁed classiﬁcation system requiring only one
imaging time point and the availability of T2LV and BPF, which does
not consider acute/recent inﬂammatory activity. We focused disease
severity rather than disease activity in creating these MRI phenotypes.
Our exploratory study should serve as a basis for conﬁrmation and
extension in future studies. A prospective study is warranted to conﬁrm
and extend these ﬁndings. While the overall sample size was large for
an MS-MRI clinical correlation study, the numbers of patients assigned
to Type II and Type III were relatively small. It remains to be determined
whether consideration of other advanced structural aspects of MRI-
deﬁned CNS related damage [7] such as imaging parameters focused
on the graymatter, spinal cord, normal-appearingwhitematter, destruc-
tive potential of lesions, or mapping of speciﬁc sites/tracts of involve-
ment would help to further reﬁne the MRI phenotype deﬁnitions.
Given the emerging data suggesting a link between genetics, immuneregulation, and inﬂammatory or neurodegenerative aspects of MS
disease pathogenesis [29–35], it would be of interest to investigate if
the MRI phenotypes are associated with speciﬁc biomarkers. Because
most of our patients were treated with disease modifying medications,
this might alter the natural rate or degree of development lesion and
atrophy metrics. It would be of interest to assess if these phenotypic
deﬁnitions persist when considering untreated patients. This may not
be feasible in the current treatment era, requiring access to historic
data sets. Finally, it remains to be determined in longitudinal studies,
the treatment response and rate/factors associated with a change in a
patient's MRI phenotype.
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